ValuEngine upgraded shares of KemPharm (NASDAQ:KMPH) from a strong sell rating to a sell rating in a research report report published on Friday morning.
Other research analysts have also issued reports about the company. Zacks Investment Research lowered KemPharm from a buy rating to a hold rating in a research report on Thursday, November 16th. Royal Bank of Canada set a $9.00 target price on KemPharm and gave the stock a buy rating in a research report on Tuesday, January 16th. Oppenheimer set a $13.00 target price on KemPharm and gave the stock a buy rating in a research report on Sunday, February 25th. Finally, Canaccord Genuity set a $11.00 target price on KemPharm and gave the stock a buy rating in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $9.15.
KemPharm (NASDAQ:KMPH) opened at $6.80 on Friday. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a 52-week low of $2.45 and a 52-week high of $7.45.
ILLEGAL ACTIVITY WARNING: “KemPharm (KMPH) Upgraded to “Sell” by ValuEngine” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3257570/kempharm-kmph-upgraded-to-sell-by-valuengine.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.